Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study

Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study

Abstract Background In Switzerland, rituximab (RTX) is licenced for the treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitis (AAV) but is frequently used off-label to treat other auto-immune diseases (AID), especially connective tissue diseases (CTD). We aimed to characterise the us...

Full description

Bibliographic Details
Main Authors:	Alexandre Dumusc, Fahad Alromaih, Matthieu Perreau, Thomas Hügle, Pascal Zufferey, Diana Dan
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	Arthritis Research & Therapy
Subjects:	Rituximab Off-label Auto-immune diseases Drug retention rate Rheumatoid arthritis Connective tissue disease
Online Access:	https://doi.org/10.1186/s13075-023-03076-w

Similar Items

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis
by: A Finckh, et al.
Published: (2010-07-01)

The profile of use of rituximab in tertiary care hospitals of central India
by: Alok Singh, et al.
Published: (2022-01-01)

The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
by: Šekib Sokolović, et al.
Published: (2010-05-01)

Perspectives of the treatment of rheumatic diseases in the beginning of the XXI century
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-05-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)

THE EFFICACY AND SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: D. A. Kusevich, et al.
Published: (2017-09-01)

Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
by: Mohammed Abdullah Saleem, et al.
Published: (2024-12-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
by: A V Bezgin, et al.
Published: (2011-08-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. I. Feiskhanova
Published: (2018-11-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study
by: Suhel Gabriele Al Khayyat, et al.
Published: (2021-08-01)

A Rare Case of Disseminated Histoplasmosis with Oral Manifestations in a Rheumatoid Arthritis Patient Treated with Rituximab Diagnostic and Management Challenges – A Review
by: Shruti Bajad, et al.
Published: (2020-01-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2011-02-01)

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
by: A. A. Novikov, et al.
Published: (2011-06-01)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
by: Levent Kilic, et al.
Published: (2018-11-01)

Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
by: Antonios Bertsias, et al.
Published: (2022-06-01)

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE
by: A. S. Avdeeva, et al.
Published: (2017-07-01)

Rituximabe na síndrome de Felty refratária Rituximab in the refractory Felty's syndrome
by: Thiago Sotero Fragoso, et al.
Published: (2009-04-01)

Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
by: Maurizio Benucci, et al.
Published: (2009-03-01)

Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
by: Narendra Maharaj, et al.
Published: (2024-12-01)

On- and off-label use of rituximab in rheumatic diseases
by: Gilda Sandri, et al.
Published: (2021-04-01)

Acquired hemophilia A treated with rituximab in a 62-year-old female with rheumatoid arthritis: a case-based review
by: D. Mohamadzadeh, et al.
Published: (2023-12-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

Rhodococcus erythropolis Encephalitis in Patient Receiving Rituximab
by: Satish R. Bagdure, et al.
Published: (2012-08-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
by: A. S. Avdeeva, et al.
Published: (2022-06-01)

Efficacy, Safety and Predictors of Response to Rituximab in Treatment of Iraqi Patients with Active Rheumatoid Arthritis
by: Sarah Tareq Abdulazeez, et al.
Published: (2019-06-01)

Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis
by: Evgenija Mihajloska, et al.
Published: (2024-06-01)

Effect of Rituximab on the circulating levels of cytokines produced or not produced by B lymphocytes in patients with rheumatoid arthritis
by: Segura-González, Angie Katherine, et al.
Published: (2022-07-01)

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases
by: Manuel Pombo-Suárez, et al.
Published: (2023-06-01)

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis
by: Aleksandr Vital'evich Volkov, et al.
Published: (2010-12-01)

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies
by: Nadia M. T. Roodenrijs, et al.
Published: (2018-11-01)

EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS
by: Tatyana Valentinovna Popkova, et al.
Published: (2010-08-01)

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunityResearch in context
by: James I. Robinson, et al.
Published: (2022-12-01)

Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
by: Mie Jin Lim, et al.
Published: (2023-11-01)

Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab
by: Daniela Viecceli, et al.